SCHEMBL20869833

SCHEMBL20869833

O=C(CCCCC(=O)Oc1c(F)c(F)c(F)c(F)c1F)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 2/20 0.41
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
KDM4E B2RXH2 4/20 0.40
POLB P06746 1/20 0.40
UCHL1 P09936 1/20 0.40
USP5 P45974 1/20 0.40
USP4 Q13107 1/20 0.40
SENP1 Q9P0U3 1/20 0.40
ALDH1A1 P00352 4/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
RECQL P46063 1/20 0.38
PAM P19021 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
AKR1B1 P15121 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6937307 0.82 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1TSHRKMT2AMEN1
SCHEMBL20673370 0.82 ALDH1A1 (0.50) SMN1; SMN2L3MBTL1TDP1TSHRKMT2A
SCHEMBL26315892 0.81 ALDH1A1 (0.49) SMN1; SMN2L3MBTL1TDP1KMT2AMEN1
SCHEMBL22499185 0.80 TDP1 (0.58) SMN1; SMN2L3MBTL1TDP1TSHRKMT2A
SCHEMBL16217874 0.79 ALDH1A1 (0.50) SMN1; SMN2L3MBTL1TDP1TSHRKMT2A
SCHEMBL4953772 0.79 KMT2A (0.44) TSHRKMT2AMEN1KDM4EALDH1A1
SCHEMBL25495837 0.77 KMT2A (0.43) TSHRKMT2AMEN1KDM4EALDH1A1
SCHEMBL21049231 0.77 KMT2A (0.43) TSHRKMT2AMEN1KDM4EALDH1A1
SCHEMBL522462 0.77 KMT2A (0.43) TSHRKMT2AMEN1KDM4EALDH1A1
SCHEMBL11062372 0.76 LMNA (0.59) L3MBTL1TDP1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210009580-A1 AZTREONAM DERIVATIVES AND USES THEREOF ARIXA PHARMACEUTICALS, INC. 2021-01-14 US disclosed
US-10815228-B2 Aztreonam derivatives and uses thereof ARIXA PHARMACEUTICALS, INC. (US) 2020-10-27 US disclosed
US-20190211006-A1 AZTREONAM DERIVATIVES AND USES THEREOF ARIXA PHARMACEUTICALS, INC. 2019-07-11 US disclosed
US-10280161-B2 Aztreonam derivatives and uses thereof ARIXA PHARMACEUTICALS, INC. (US) 2019-05-07 US disclosed
WO-2019070595-A1 AZTREONAM DERIVATIVES AND USES THEREOF ARIXA PHARMACEUTICALS, INC. (US) 2019-04-11 WO disclosed
US-20190100516-A1 AZTREONAM DERIVATIVES AND USES THEREOF ARIXA PHARMACEUTICALS, INC. 2019-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280161-B2 Aztreonam derivatives and uses thereof MGAM, ABCG2, SI SMN1; SMN2 3921/4885L3MBTL1 2241/4885TDP1 2196/4885
US-20190211006-A1 AZTREONAM DERIVATIVES AND USES THEREOF MGAM, ABCG2, SI SMN1; SMN2 3921/4885L3MBTL1 2241/4885TDP1 2196/4885
US-20190100516-A1 AZTREONAM DERIVATIVES AND USES THEREOF MGAM, ABCG2, SI SMN1; SMN2 3921/4885L3MBTL1 2241/4885TDP1 2196/4885
US-10815228-B2 Aztreonam derivatives and uses thereof MGAM, ABCG2, SI SMN1; SMN2 3921/4885L3MBTL1 2241/4885TDP1 2196/4885
US-20210009580-A1 AZTREONAM DERIVATIVES AND USES THEREOF MGAM, ABCG2, SI SMN1; SMN2 3921/4885L3MBTL1 2241/4885TDP1 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.